Immune marker signature helps to predict survival in uveal melanoma

被引:6
|
作者
Pan, Li-Sha [1 ]
Ackbarkha, Zacharia [1 ]
Zeng, Jing [1 ]
Huang, Min-Li [1 ]
Yang, Zhen [2 ]
Liang, Hao [1 ]
机构
[1] Guangxi Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanning 530021, Peoples R China
[2] 923 Hosp Chinese Peoples Liberat Army, Dept Geriatr, Nanning 530021, Peoples R China
关键词
immune index; uveal melanoma; stromal index; tumor microenvironment; prognosis; IFN-GAMMA; EXPRESSION; INVASION;
D O I
10.3934/mbe.2021203
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The detailed molecular function of tumor microenvironment (TEM) in uveal melanoma (UVM) remains unclear. This study generated the immune index and the stromal index scores by ESTIMATE algorithm based on RNA-sequencing data with 80 UVM patients. There was no correlation between the immune stromal index and clinical parameters. The differentially expressed genes related to the immune stromal index were calculated and were described by functional annotations and protein-protein interaction network diagrams. After univariate and multivariate Cox regression analyses, there were four genes (HLA-J, MMP12, HES6, and ADAMDEC1) with significant prognostic significance. The prognostic model was constructed using these four characteristic genes, and the KM curve and tROC curve were described to show that the model had a better ability to predict survival outcomes and prognosis. The verification results in GSE62075 showed that HLA-J and HES6 were expressed differently in the cancer group than in the non-cancer group. This study indicates that the risk signature based on the immune index can be used as an indicator to evaluate the prognosis of patients with UVM.
引用
收藏
页码:4055 / 4070
页数:16
相关论文
共 50 条
  • [41] Survival in patients with uveal melanoma in Europe
    Virgili, Gianni
    Gatta, Gemma
    Ciccolallo, Laura
    Capocaccia, Riccardo
    Biggeri, Annibale
    Crocetti, Emanuele
    Lutz, Jean-Michel
    Paci, Eugenio
    ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (10) : 1413 - 1418
  • [42] Tantalum marker number in the treatment of uveal melanoma
    Poothullil, AM
    Hayes, DJC
    Daftari, IK
    O'Brien, JM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U251 - U251
  • [43] PREDICTING SURVIVAL OF UVEAL MELANOMA PATIENTS
    GAMEL, JW
    OPHTHALMOLOGY, 1989, 96 (04) : 570 - 570
  • [44] Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival
    Micevic, Goran
    Muthusamy, Viswanathan
    Pupo, Gulietta
    Scolyer, Richard
    Long, Georgina
    Bosenberg, Marcus
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E9 - E9
  • [45] An immune infiltration signature to predict the overall survival of patients with colon cancer
    Peng, Dengfa
    Wang, Lianjun
    Li, Huqing
    Cai, Changsong
    Tan, Yong
    Xu, Bin
    Le, Hao
    IUBMB LIFE, 2019, 71 (11) : 1760 - 1770
  • [46] An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients
    Pengfei Xia
    Qing Li
    Guanlin Wu
    Yimin Huang
    Cellular and Molecular Neurobiology, 2021, 41 : 365 - 375
  • [47] An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients
    Xia, Pengfei
    Li, Qing
    Wu, Guanlin
    Huang, Yimin
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2021, 41 (02) : 365 - 375
  • [48] Identification of Survival-Related Metabolic Genes and a Novel Gene Signature Predicting the Overall Survival for Patients with Uveal Melanoma
    Guo, Xiaoyu
    Yu, Xin
    Li, Fang
    Xia, Qinyun
    Ren, He
    Chen, Zhen
    Xing, Yiqiao
    OPHTHALMIC RESEARCH, 2022, 65 (05) : 516 - 528
  • [49] SGSM2 in Uveal Melanoma: Implications for Survival, Immune Infiltration, and Drug Sensitivity
    Liang, Demao
    Zhang, Qiuli
    Pang, Yanhua
    Yan, Rili
    Ke, Yi
    PROTEIN AND PEPTIDE LETTERS, 2024, 31 (11): : 894 - 905
  • [50] A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma
    Lv, Wenchang
    Zhan, YuanYuan
    Tan, Yufang
    Wu, Yiping
    Chen, Hongbo
    FRONTIERS IN PHARMACOLOGY, 2022, 13